SCHEMBL10277787

SCHEMBL10277787

O=C(O)c1ccc(CSc2c(Cl)ccc3c2CCCCC3)cc1F

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.47
RXRB P28702 3/20 0.47
RXRG P48443 3/20 0.47
PTPRG P23470 6/20 0.43
PTPRC P08575 5/20 0.43
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
GFER P55789 1/20 0.38
MAPT P10636 1/20 0.36
PARP1 P09874 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
FABP4 P15090 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CPT2 P23786 1/20 0.33
CPT1A P50416 1/20 0.33
CPT1B Q92523 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10277974 0.89 RXRA (0.41) RXRARXRBRXRGPTPRGPTPRC
SCHEMBL10278028 0.83 MEN1 (0.33) RXRARXRBRXRGPTPRGPTPRC
SCHEMBL10277531 0.83 KMT2A (0.46) RXRARXRBRXRGPTPRGGFER
SCHEMBL506745 0.80 ESR2 (0.41) RXRARXRBRXRGPTPRGPTPRC
SCHEMBL10476170 0.79 NPC1 (0.43) PARP1SMN1; SMN2
Hydrochloric Acid SCHEMBL508519 0.78 NPC1 (0.43) PARP1SMN1; SMN2
SCHEMBL10274944 0.78 PTPRG (0.34) PTPRGPTPRCHTTMAPTNPSR1
SCHEMBL10277475 0.77 HTT (0.34) PTPRGHTTNPSR1L3MBTL1LMNA
SCHEMBL10274868 0.77 KMT2A (0.38) RXRARXRBRXRGHTTGFER
SCHEMBL10277979 0.77 POLB (0.39) PTPRGPTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 RXRA 861/4885RXRB 860/4885RXRG 786/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A RXRA 1616/4885RXRB 1847/4885RXRG 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.